Trial Review

The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
ACTRN12617001002370
Ethics application status
Approved
Date submitted
11/07/2017
Date registered
12/07/2017
Date last updated
26/10/2021
Date data sharing statement initially provided
26/10/2021
Type of registration
Retrospectively registered

Titles & IDs
Public title
Comparative assessment of the absorption of a generic formulation of 2-methyl-1-phenylpropan-2-amine (122-09-8) capsule against the innovator 2-methyl-1-phenylpropan-2-amine (122-09-8) capsule conducted under fasting condition in healthy male and female volunteers.
Scientific title
A single dose, randomized, blinded, bioequivalence study of a test formulation of 2-methyl-1-phenylpropan-2-amine (122-09-8) capsule in a 2 way crossover comparison against the innovator 2-methyl-1-phenylpropan-2-amine (122-09-8) capsule conducted under fasting conditions in healthy male and female volunteers.
Secondary ID [1] 292057 0
Nil
Universal Trial Number (UTN)
U1111-1197-1623
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
2-methyl-1-phenylpropan-2-amine (122-09-8) is a C5 Controlled Drug indicated in the management of obesity as a short-term adjunct in a medically monitored comprehensive regime of weight reduction. 303897 0
Condition category
Condition code
Diet and Nutrition 303264 303264 0 0
Obesity

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Single dose, crossover study design whereby each participant receives the test formulation of 40 mg 2-methyl-1-phenylpropan-2-amine (122-09-8) capsule on one occasion and the innovator formulation of 40 mg 2-methyl-1-phenylpropan-2-amine (122-09-8) capsule on one occasion with each dose separated by a two week washout period. The intervention for this trial is the test tablet formulation.
No water is allowed for 1 hour prior to dosing until 1 hour after dosing (except for water consumed with the dose).
Participants are required not to eat for 10 hours before receiving each dose and to fast for approximately 4 hours after receiving each dose. Bathroom visits will be confined at the Clinical Site for 10 hours prior to dosing to ensure compliance and will be monitored for 24 hours after dosing.
Standard meals will be consumed at the Clinical Site with no additional food intake allowed. Alcohol breath testing will be performed upon each participant reporting to the Clinical Site 10 hours prior to dosing.
Pre and post study laboratory tests will be completed to assess the health of participants along with HIV, Hepatitis and drugs of abuse testing.
Each dose ( 1 x. 40 mg) will be taken orally with 240 ml of water at ambient temperature. Medication must be swallowed whole and a mouth check will be conducted to ensure the medication has been taken as directed.
Intervention code [1] 298526 0
Treatment: Drugs
Comparator / control treatment
Single dose, crossover study whereby each participant receives the test formulation (1 x 40 mg) on one occasion and the innovator formulation of 2-methyl-1-phenylpropan-2-amine (122-09-8) (1 x 40 mg) on one occasion with each dose separated by a two week washout period. The comparator/control for this trial is the innovator capsule formulation.
Control group
Active

Outcomes
Primary outcome [1] 302640 0
To compare the bioavailability of 2-methyl-1-phenylpropan-2-amine (122-09-8) (as summarised by Cmax and AUC) for the formulation. All plasma samples will be assayed for 2-methyl-1-phenylpropan-2-amine (122-09-8) using a fully validated LC/MS/MS method. Validation will be conducted to comply with EU and FDA guidelines.
Timepoint [1] 302640 0
0, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 16, 20, 24, 32, 48, 56 and 72 hours post dosing.
Secondary outcome [1] 336621 0
The to maximum peak concentration (Tmax) will be determined by plasma sample analysis. Tmax will be the time where the maximum concentration occurred in the sample points.
Timepoint [1] 336621 0
0, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 16, 20, 24, 32, 48, 56 and 72 hours post dosing.

Eligibility
Key inclusion criteria
Healthy males and non-pregnant female volunteers.
Aged between 18 and 55
Non-smoker
BMI between 18.5 and 30
Normal, healthy individuals as determined by medical history, physical examination, ECG, blood pressure and laboratory tests
Able to provide written informed consent
Minimum age
18 Years
Maximum age
55 Years
Sex
Both males and females
Can healthy volunteers participate?
Yes
Key exclusion criteria
Any history of recent recurrent attacks of bronchitis, asthma, migraine headaches
Concomitant drug therapy of any kind
Any history of heart problems
Sensitivity to the study drug
History of any conditions that might interfere with the absorption, distribution, metabolism or excretion of the drug
Females who are pregnant and/or breastfeeding
Smoker (anyone who has smoked in the last 6 months)
History of alcohol or drug abuse or dependency
Participation in a drug study within 60 days of the start of the study or donated blood within the 60 days preceding the study
Volunteers for whom the Clinical Investigator believer, for any reason, that participation would not be an acceptable risk

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
All formulations will be labelled as Formulation A and B. The identi cation of each treatment will only be known to the Managing Director and the Section Head - Trails and Regulatory A airs.
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Each participant will be given a 3 digit screening number and a 2 digit subject number. The screening number will be issued once the participant has given written consent to participate in the study and the two digit subject number (randomisation number) after acceptance into the study. Sequence generation will be by using a simple randomisation using a randomisation table created by computer software (i.e. computerised sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Crossover
Other design features
Phase
Phase 1
Type of endpoint/s
Bio-equivalence
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Date of first participant enrolment
Anticipated
14/07/2017
Actual
14/04/2017
Date of last participant enrolment
Anticipated
Actual
14/04/2017
Date of last data collection
Anticipated
Actual
1/08/2017
Sample size
Target
24
Accrual to date
Final
21
Recruitment outside Australia
Country [1] 9037 0
New Zealand
State/province [1] 9037 0
Otago

Funding & Sponsors
Funding source category [1] 296590 0
Commercial sector/Industry
Name [1] 296590 0
Aspen Australia
Country [1] 296590 0
Australia
Primary sponsor type
Commercial sector/Industry
Name
Zenith Technology Corporation Limited
Address
156 Frederick Street
Dunedin 9016
Country
New Zealand
Secondary sponsor category [1] 295542 0
None
Name [1] 295542 0
Address [1] 295542 0
Country [1] 295542 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 297811 0
Central Health and Disability Ethics Committee
Ethics committee address [1] 297811 0
Ethics committee country [1] 297811 0
New Zealand
Date submitted for ethics approval [1] 297811 0
16/06/2017
Approval date [1] 297811 0
10/07/2017
Ethics approval number [1] 297811 0
17/CEN/110

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 75170 0
Dr Noelyn Hung
Address 75170 0
Zenith Technology Corporation Limited
156 Frederick Street (PO Box 1777)
Dunedin 9016
Country 75170 0
New Zealand
Phone 75170 0
+6434779669
Fax 75170 0
+6434779605
Email 75170 0
[email protected]
Contact person for public queries
Name 75171 0
Linda Folland
Address 75171 0
Zenith Technology Corporation Limited
156 Frederick Street (PO Box 1777)
Dunedin 9016
Country 75171 0
New Zealand
Phone 75171 0
+6434779669
Fax 75171 0
+6434779605
Email 75171 0
[email protected]
Contact person for scientific queries
Name 75172 0
Tak Hung
Address 75172 0
Zenith Technology Corporation Limited
156 Frederick Street (PO Box 1777)
Dunedin 9016
Country 75172 0
New Zealand
Phone 75172 0
+6434779669
Fax 75172 0
+6434779605
Email 75172 0
[email protected]

Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
No
No/undecided IPD sharing reason/comment
All data will be compiled into a final report that is the property of the sponsor company. All participant data will be provided in summary format and result of the study only will be reported.


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.